DK0621898T3 - Kimæriske immunogener - Google Patents

Kimæriske immunogener

Info

Publication number: DK0621898T3
Authority: DK; Denmark
Prior art keywords: protein; piv; rsv; gene sequence; pathogen
Prior art date: 1992-01-06

Application number

DK93901988T

Other languages

English (en)

Inventor

Michel H Klein

Run-Pan Du

Mary E Ewasyshyn

Original Assignee

Aventis Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-06

Filing date

1993-01-05

Publication date

2001-11-12

1993-01-05 Application filed by Aventis Pasteur filed Critical Aventis Pasteur

2001-11-12 Application granted granted Critical

2001-11-12 Publication of DK0621898T3 publication Critical patent/DK0621898T3/da

Links

108090000623 proteins and genes Proteins 0.000 abstract 5
241000725643 Respiratory syncytial virus Species 0.000 abstract 3
244000052769 pathogen Species 0.000 abstract 3
230000000890 antigenic effect Effects 0.000 abstract 2
230000001717 pathogenic effect Effects 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
241000700605 Viruses Species 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G01N2333/135—Respiratory syncytial virus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK93901988T 1992-01-06 1993-01-05 Kimæriske immunogener DK0621898T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929200117A GB9200117D0 (en)	1992-01-06	1992-01-06	Production of recombinant chimeric proteins for vaccine use
PCT/CA1993/000001 WO1993014207A1 (en)	1992-01-06	1993-01-05	Chimeric immunogens

Publications (1)

Publication Number	Publication Date
DK0621898T3 true DK0621898T3 (da)	2001-11-12

Family

ID=10708117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93901988T DK0621898T3 (da)	1992-01-06	1993-01-05	Kimæriske immunogener

Country Status (16)

Country	Link
US (13)	US6225091B1 (da)
EP (1)	EP0621898B1 (da)
JP (1)	JP3290662B2 (da)
KR (1)	KR100208310B1 (da)
AT (1)	ATE205535T1 (da)
AU (1)	AU667502B2 (da)
CA (1)	CA2126863C (da)
DE (1)	DE69330745T2 (da)
DK (1)	DK0621898T3 (da)
ES (1)	ES2164070T3 (da)
FI (1)	FI117514B (da)
GB (1)	GB9200117D0 (da)
NO (1)	NO316622B1 (da)
PT (1)	PT621898E (da)
RU (1)	RU2123047C1 (da)
WO (1)	WO1993014207A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9200117D0 (en) *	1992-01-06	1992-02-26	Connaught Lab	Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en)	1993-06-07	2002-11-12	Trimeris, Inc.	Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2718452B1 (fr)	1994-04-06	1996-06-28	Pf Medicament	Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6300090B1 (en)	1994-07-29	2001-10-09	The Rockefeller University	Methods of use of viral vectors to deliver antigen to dendritic cells
US20030054505A1 (en) *	1997-09-26	2003-03-20	Hong Jin	Recombinant rsv expression systems and vaccines
FR2726472B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US7485440B2 (en)	1995-09-27	2009-02-03	The United States Of America As Represented By The Department Of Health And Human Services	Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP0912724B1 (en)	1996-07-15	2009-12-09	The Government of The United States of America, as represented by The Department of Health and Human Services	Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en)	1996-07-15	2004-03-02	Peter L. Collins	Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
FR2751229B1 (fr) *	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7632508B2 (en)	1997-05-23	2009-12-15	The United States Of America	Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en)	1997-05-23	2011-05-31	The United States Of America As Represented By The Department Of Health And Human Services	Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en)	1997-05-23	2007-04-10	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6410023B1 (en)	1997-05-23	2002-06-25	United States Of America	Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7192593B2 (en) *	1997-05-23	2007-03-20	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7314631B1 (en)	1997-05-23	2008-01-01	The United States Of America As Represented By The Department Of Health And Human Services	Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US20030082209A1 (en)	2000-07-05	2003-05-01	Skiadopoulos Mario H.	Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en)	1997-05-23	2007-07-31	United States Of America As Represented By The Dept. Of Health & Human Services	Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US6258782B1 (en)	1998-05-20	2001-07-10	Trimeris, Inc.	Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en)	1998-05-20	2003-12-02	Trimeris, Inc.	Hybrid polypeptides with enhanced pharmacokinetic properties
AU5980899A (en) *	1998-09-25	2000-04-17	Smithkline Beecham Biologicals (Sa)	Novel compounds
CN100354425C (zh)	1999-07-09	2007-12-12	美国政府健康及人类服务部	减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
KR100940776B1 (ko) *	1999-07-09	2010-02-11	더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈	약독화된 사람-소 키메라 파라인플루엔자바이러스(ｐｉｖ) 백신
US6764685B1 (en)	2000-03-21	2004-07-20	Medimmune Vaccines, Inc.	Recombinant parainfluenza virus expression systems and vaccines
US20030232055A1 (en) *	2000-07-31	2003-12-18	Ruslan Medzhitov	Innate immune system-directed vaccines
US20030175287A1 (en) *	2001-01-03	2003-09-18	Yale University	Innate immune system-directed vaccines
SG149684A1 (en)	2001-01-19	2009-02-27	Vironovative Bv	A virus causing respiratory tract illness in susceptible animals
US8715922B2 (en)	2001-01-19	2014-05-06	ViroNovative	Virus causing respiratory tract illness in susceptible mammals
KR101076102B1 (ko)	2002-02-21	2011-10-21	비로노바티브 비.브이.	메타뉴모바이러스에서 유래한 이종성 항원을 포함하는재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
JP4448440B2 (ja) *	2002-04-30	2010-04-07	株式会社ディナベック研究所	プロテアーゼ依存性トロピズムが改変されたベクター
WO2004010935A2 (en) *	2002-07-25	2004-02-05	Medimmune, Inc.	Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US20060110740A1 (en) *	2003-01-20	2006-05-25	Julia Hurwitz	Use of sendai virus as a human parainfluenza vaccine
ATE469170T1 (de) *	2003-03-28	2010-06-15	Medimmune Llc	Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CA2523319A1 (en)	2003-04-25	2004-11-11	Medimmune Vaccines, Inc.	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CA2594612A1 (en) *	2005-01-19	2006-07-27	Vaxinnate Corporation	Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
ES2555544T3 (es)	2006-03-07	2016-01-04	Vaxinnate Corporation	Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
DE102006060799A1 (de)	2006-12-21	2008-06-26	RUHR-UNIVERSITäT BOCHUM	RSV F-Protein und seine Verwendung
WO2010086743A2 (en)	2009-02-02	2010-08-05	Chrontech Pharma Ab	Compositions and methods that enhance an immune response
MX2012000036A (es) *	2009-06-24	2012-02-28	Glaxosmithkline Biolog Sa	Vacuna.
WO2012103496A2 (en) *	2011-01-28	2012-08-02	Medimmune, Llc	Expression of soluble viral fusion glycoproteins in mammalian cells
EP2752199A4 (en)	2011-08-29	2015-04-29	Univ Tokushima	RSV MUCOSA VACCINE
EP2785370B1 (en)	2011-12-02	2021-07-21	Rhode Island Hospital	Vaccine for falciparum malaria
EA201891945A3 (ru)	2012-08-01	2019-05-31	Бавариан Нордик А/С	Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
WO2014186409A1 (en)	2013-05-15	2014-11-20	Chrontech Pharma Ab	Immunogenic compositions for inhibiting hepatitis d virus
MD3718565T2 (ro)	2015-10-22	2022-09-30	Modernatx Inc	Vaccinuri împotriva virusului respirator
EP3551193A4 (en)	2016-12-08	2020-08-19	Modernatx, Inc.	NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018170347A1 (en)	2017-03-17	2018-09-20	Modernatx, Inc.	Zoonotic disease rna vaccines
US11351242B1 (en)	2019-02-12	2022-06-07	Modernatx, Inc.	HMPV/hPIV3 mRNA vaccine composition
WO2026092136A1 (en) *	2024-10-28	2026-05-07	Sichuan Clover Biopharmaceuticals, Inc.	Combo vaccines for respiratory diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en) *	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US4866034A (en) *	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
SE8205892D0 (sv) *	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3584866D1 (de) *	1984-09-12	1992-01-23	Chiron Corp	Hybridpartikel-immunogene.
IL76751A (en) *	1984-11-01	1991-04-15	American Home Prod	Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
US4722898A (en) *	1985-04-29	1988-02-02	Minnesota Mining And Manufacturing Company	Immobilization of biological cells in polytetrafluoroethylene matrix
GB8610983D0 (en) *	1986-05-06	1986-06-11	Connaught Lab	Enhancement of antigen immunogenicity
US4879213A (en) *	1986-12-05	1989-11-07	Scripps Clinic And Research Foundation	Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098998A (en) *	1987-04-29	1992-03-24	President And Fellows Of Harvard College	Cholera vaccines and peptides
EP0316695B1 (de) *	1987-11-16	1993-03-31	F. Hoffmann-La Roche Ag	Rekombinante HIV-2 Polypeptide
US5194595A (en) *	1987-12-23	1993-03-16	The Upjohn Company	Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
DE68915165T2 (de) *	1988-04-22	1994-09-08	Upjohn Co	Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
FR2636842B1 (fr)	1988-09-27	1994-06-10	Liege Universite Etat	Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0421626A1 (en)	1989-09-19	1991-04-10	Merck & Co. Inc.	Vaccine for aids and hepatitis B
GB9200117D0 (en) *	1992-01-06	1992-02-26	Connaught Lab	Production of recombinant chimeric proteins for vaccine use
IL105456A (en)	1992-04-21	1996-12-05	American Home Prod	Vaccines of attenuated respiratory syncytial virus

1992
- 1992-01-06 GB GB929200117A patent/GB9200117D0/en active Pending
1993
- 1993-01-05 CA CA002126863A patent/CA2126863C/en not_active Expired - Lifetime
- 1993-01-05 DK DK93901988T patent/DK0621898T3/da active
- 1993-01-05 AT AT93901988T patent/ATE205535T1/de active
- 1993-01-05 WO PCT/CA1993/000001 patent/WO1993014207A1/en not_active Ceased
- 1993-01-05 PT PT93901988T patent/PT621898E/pt unknown
- 1993-01-05 AU AU33402/93A patent/AU667502B2/en not_active Expired
- 1993-01-05 DE DE69330745T patent/DE69330745T2/de not_active Expired - Lifetime
- 1993-01-05 EP EP93901988A patent/EP0621898B1/en not_active Expired - Lifetime
- 1993-01-05 ES ES93901988T patent/ES2164070T3/es not_active Expired - Lifetime
- 1993-01-05 KR KR1019940702329A patent/KR100208310B1/ko not_active Expired - Lifetime
- 1993-01-05 RU RU94042722A patent/RU2123047C1/ru active
- 1993-01-05 JP JP51203593A patent/JP3290662B2/ja not_active Expired - Lifetime
- 1993-01-06 US US08/001,554 patent/US6225091B1/en not_active Expired - Lifetime
1994
- 1994-07-05 NO NO19942530A patent/NO316622B1/no not_active IP Right Cessation
- 1994-07-05 FI FI943211A patent/FI117514B/fi not_active IP Right Cessation
- 1994-11-14 US US08/344,639 patent/US6033668A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/467,963 patent/US5968776A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,969 patent/US6168786B1/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,961 patent/US6171783B1/en not_active Expired - Lifetime
1997
- 1997-04-16 US US08/838,189 patent/US5998169A/en not_active Expired - Lifetime
- 1997-05-07 US US08/852,344 patent/US6017539A/en not_active Expired - Lifetime
2004
- 2004-05-10 US US10/842,032 patent/US7244589B2/en not_active Expired - Fee Related
2007
- 2007-06-13 US US11/808,794 patent/US7671186B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/808,807 patent/US7514535B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/808,800 patent/US7405273B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/808,802 patent/US7498153B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/808,789 patent/US7619063B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FI117514B (fi)	2006-11-15
US5998169A (en)	1999-12-07
DE69330745D1 (de)	2001-10-18
US20080311624A1 (en)	2008-12-18
US20080312412A1 (en)	2008-12-18
US20050136067A1 (en)	2005-06-23
KR100208310B1 (ko)	1999-07-15
GB9200117D0 (en)	1992-02-26
RU2123047C1 (ru)	1998-12-10
US20080032342A1 (en)	2008-02-07
US6168786B1 (en)	2001-01-02
PT621898E (pt)	2002-03-28
US7514535B2 (en)	2009-04-07
US20080027213A1 (en)	2008-01-31
EP0621898A1 (en)	1994-11-02
CA2126863A1 (en)	1993-07-22
JPH07501707A (ja)	1995-02-23
CA2126863C (en)	1999-08-10
US6033668A (en)	2000-03-07
AU3340293A (en)	1993-08-03
US6017539A (en)	2000-01-25
US6171783B1 (en)	2001-01-09
US7405273B2 (en)	2008-07-29
WO1993014207A1 (en)	1993-07-22
NO942530L (no)	1994-09-05
US7619063B2 (en)	2009-11-17
DE69330745T2 (de)	2002-05-29
US20080015340A1 (en)	2008-01-17
EP0621898B1 (en)	2001-09-12
US5968776A (en)	1999-10-19
NO942530D0 (no)	1994-07-05
ATE205535T1 (de)	2001-09-15
AU667502B2 (en)	1996-03-28
US7498153B2 (en)	2009-03-03
US6225091B1 (en)	2001-05-01
ES2164070T3 (es)	2002-02-16
JP3290662B2 (ja)	2002-06-10
NO316622B1 (no)	2004-03-15
US7671186B2 (en)	2010-03-02
FI943211A0 (fi)	1994-07-05
RU94042722A (ru)	1996-09-10
FI943211L (fi)	1994-09-02
US7244589B2 (en)	2007-07-17

Publication	Publication Date	Title
NO942530D0 (no)	1994-07-05	Chimeriske Immunogener
DK0853487T3 (da)	2000-10-23	Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
KR900700508A (ko)	1990-08-13	인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
MY103182A (en)	1993-05-29	Vaccines against acquired immune deficiency syndrome.
DK0612250T3 (da)	1996-11-25	Fremgangsmåder og præparater med relation til nyttige Moraxella catarrhalis-antigener
BG98523A (en)	1995-05-31	Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DK0759067T3 (da)	2001-10-22	Transformerende vækstfaktor alfa-H1
CA2231603A1 (en)	1997-04-24	Chicken interleukin-15 and uses thereof
DK251890A (da)	1990-10-18	Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
DK22389A (da)	1989-07-21	Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
PT666916E (pt)	2004-08-31	Antigenes de plasmodium falciparum inductores de anticorpos protectores
ATE342920T1 (de)	2006-11-15	Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
ATE355375T1 (de)	2006-03-15	Bakterioferritin aus helicobacter pylori
PT817851E (pt)	2004-06-30	Dna codificador do virus do papiloma humano tipo 18
AU626684B2 (en)	1992-08-06	Mouse monoglonal antibodies for post-exposure treatment of rabies
KR890700030A (ko)	1989-03-02	인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
ATE133708T1 (de)	1996-02-15	Immunogenisches peptid von echinococcus granulosis, dafür kodierende dns sowie diagnostische und therapeutische verwendungen
ATE248601T1 (de)	2003-09-15	Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
DK0762895T3 (da)	2002-09-02	Syntetisk vaccine til beskyttelse mod infektion med human immundefektvirus
DE69330268D1 (de)	2001-07-05	Hämoregulierende peptide
DE69102649D1 (de)	1994-07-28	Hrsv-vakzine.
DK0542895T3 (da)	1997-05-12	Krydsreaktiv influenza A immunisering
ATE138269T1 (de)	1996-06-15	Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
DE69619123D1 (de)	2002-03-21	Hämoregulatorische verbindungen
NO934547L (no)	1994-02-10	Oral behandling av Helicobacter-infeksjon